[Treatment of high blood cholesterol in patients with coronary heart disease].
Nagai
Yoshiyuki
Y
Division of Cardiology, RINKU General Medical Center.
Yamashita
Shizuya
S
D000837:Anion Exchange Resins / Q000494:pharmacology / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000378:metabolism; D002792:Cholestyramine Resin / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000209:etiology* / Q000517:prevention & control; D011345:Fenofibrate / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000150:complications* / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011322:Primary Prevention; D011341:Probucol / Q000494:pharmacology / Q000627:therapeutic use; D011973:Receptors, LDL / Q000378:metabolism; D012307:Risk Factors
D000837:Anion Exchange Resins; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011973:Receptors, LDL; D002792:Cholestyramine Resin; D011341:Probucol; D011345:Fenofibrate